ProMetic Life Sciences Inc.  

(Public, TSE:PLI)   Watch this stock  
Find more results for PLI
+0.04 (2.13%)
Delayed:   2:54PM EST
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.83 - 1.94
52 week 0.85 - 2.21
Open 1.88
Vol / Avg. 1.29M/1.02M
Mkt cap 1.05B
P/E     -
Div/yield     -
EPS -0.02
Shares 547.63M
Beta 1.23
Inst. own     -
Feb 9, 2015
ProMetic Life Sciences Inc at Biotechnology Industry Organization CEO & Investor Conference - 4:00PM EST - Add to calendar
Jan 13, 2015
ProMetic Life Sciences Inc at EBD Biotech Showcase
Nov 14, 2014
Q3 2014 ProMetic Life Sciences Inc Earnings Call
Nov 13, 2014
Q3 2014 ProMetic Life Sciences Inc Earnings Release

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -893.17% -84.28%
Operating margin -890.89% -83.64%
EBITD margin - -45.13%
Return on average assets -61.94% -47.76%
Return on average equity -217.55% -122.43%
Employees 159 -
CDP Score - -


440 Armand-Frappier Blvd Suite 300
+1-450-7810115 (Phone)
+1-450-7814477 (Fax)

Website links


ProMetic Life Sciences Inc. (ProMetic) is a bio-pharmaceutical company offering technologies for large-scale drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens, The Company focuses its activities in two segments: protein technologies and therapeutics. It develops therapeutics to treat blood-related disorders. Its protein technologies are used to remove pathogens from blood and extract and recover proteins from plasma. The Company is developing products to treat anemia, neutropenia, cancer and autoimmune disease/inflammation. ProMetic uses its Affinity Technology, which employs its Mimetic Ligand technology (chemical hooks that selectively recognize and bind to target biomolecules) to facilitate a variety of applications, where a target biomolecule requires purification or removal. Effective May 9, 2014, the Company raised its interest to 60% from 10% by acquiring a 50% interest in NantPro Biosciences LLC.

Officers and directors

G. F. Kym Anthony Independent Chairman of the Board
Age: 58
Pierre Laurin Ph.D. President, Chief Executive Officer, Director
Bruce Pritchard Chief Financial Officer, Chief Operating Officer
Steve J. Burton Chief Executive Officer of ProMetic BioSciences Ltd.
Age: 62
Patrick Sartore General Counsel, Corporate Secretary
John Moran M.D. Chief Medical Officer, Director
Age: 68
Dwun-Hou Chen Ph.D. Senior Vice President, Product and Asia Pacific Development of ProMetic BioTherapeutics, Inc.
Stefan Clulow Director
Charles Kenworthy Director
Age: 56
Bruce J. Wendel Director
Age: 60